Neuropathix, Inc.
NPTX · OTC
3/31/2022 | 12/31/2021 | 9/30/2021 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $208 | $151 | $0 | $0 |
| % Growth | 37.3% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $208 | $151 | $0 | $0 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $220 | $168 | $79 | $76 |
| G&A Expenses | $355 | $615 | $485 | $585 |
| SG&A Expenses | $355 | $615 | $485 | $585 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$208 | $35 | -$35 | $0 |
| Operating Expenses | $366 | $666 | $529 | $661 |
| Operating Income | $558 | -$666 | -$529 | -$661 |
| % Margin | 268.5% | -439.7% | – | – |
| Other Income/Exp. Net | -$1,229 | -$91 | -$192 | -$90 |
| Pre-Tax Income | -$1,596 | -$757 | -$721 | -$751 |
| Tax Expense | $305 | $0 | $0 | $0 |
| Net Income | -$1,900 | -$757 | -$721 | -$751 |
| % Margin | -913.6% | -499.6% | – | – |
| EPS | -0.021 | -0.009 | -0.008 | -0.009 |
| % Growth | -139.5% | -7.5% | 5.9% | – |
| EPS Diluted | -0.021 | -0.009 | -0.008 | -0.009 |
| Weighted Avg Shares Out | 92,349 | 87,933 | 90,276 | 87,978 |
| Weighted Avg Shares Out Dil | 92,349 | 87,933 | 90,276 | 87,978 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $305 | $71 | $118 | $111 |
| Depreciation & Amortization | $32 | $7 | $5 | $5 |
| EBITDA | $591 | -$607 | -$480 | -$525 |
| % Margin | 284% | -400.7% | – | – |